Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Dengue virus serotype 2 envelope protein (DENV-2 E) is the major structural glycoprotein found on the outer surface of the DENV-2 virion. It plays a critical role in the viral life cycle by mediating host cell receptor binding, attachment, and subsequent low-pH-triggered membrane fusion within the endosome to release the viral genome into the host cytoplasm. Structurally, the E protein exists as a flat homodimer on mature virions and undergoes a major conformational transition to a post-fusion homotrimer during entry. Because of its essential role in viral entry and its high exposure on the virion surface, DENV-2 E is a primary target for neutralizing antibodies, therapeutic monoclonal antibodies (such as VIS513 and HMAb 2D22), and small-molecule fusion inhibitors. It is also the key antigen component in licensed vaccines like Dengvaxia and Qdenga, which aim to elicit protective neutralizing antibody responses. However, targeting this protein carries significant therapeutic challenges, most notably antibody-dependent enhancement (ADE), where sub-neutralizing or cross-reactive antibodies facilitate viral entry into Fc-receptor-bearing cells, potentially leading to severe dengue hemorrhagic fever or dengue shock syndrome.
Drugs and vaccines targeting the Dengue virus serotype 2 envelope protein work by either blocking viral entry (by preventing host cell receptor binding, attachment, or low-pH-mediated membrane fusion) or by acting as immunogens in vaccines to elicit protective neutralizing antibody responses.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dengue virus serotype 2 envelope protein (DENV-2 E).